Panitumumab in combination with preoperative radiotherapy in patients with locally advanced RAS wildtyp rectal cancer. Results of the multicenter explorative single-arm phase II study NEORIT

Studies investigating combinations of anti-epidermal growth factor receptor monoclonal antibodies such as panitumumab or cetuximab with standard chemoradiotherapy protocols in rectal cancer yielded disappointing results. Because of the supposed negative interaction of EGFR-inhibition and chemoradiotherapy we conducted a phase II-study using single agent panitumumab in combination with RT in patients with RAS wildtype with locally advanced rectal cancer.

from α1 via xlomafota.13 on Inoreader http://ift.tt/2sTjD2A
via IFTTT